The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High affinity CD3 RECRUIT TandAb for T cell-mediated lysis of CD19+ tumor B cells.
Eugene Zhukovsky
Employment or Leadership Position - Affimed Therapeutics
Stock Ownership - Affimed Therapeutics
Other Remuneration - Affimed Therapeutics
Uwe Reusch
Employment or Leadership Position - Affimed Therapeutics
Carmen Burkhardt
Employment or Leadership Position - Affimed Therapeutics
Stefan Knackmuss
Employment or Leadership Position - Affimed Therapeutics
Ivica Fucek
Employment or Leadership Position - Affimed Therapeutics
Markus Eser
Employment or Leadership Position - Affimed Therapeutics
Fionnuala McAleese
Employment or Leadership Position - Affimed Therapeutics
Kristina Ellwanger
Employment or Leadership Position - Affimed Therapeutics
Consultant or Advisory Role - Affimed Therapeutics
Stock Ownership - Affimed Therapeutics
Melvyn Little
Employment or Leadership Position - Affimed Therapeutics
Consultant or Advisory Role - Affimed Therapeutics
Stock Ownership - Affimed Therapeutics